| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Renal Transplantation |
,
* Divisions of Nephrology, Hypertension and Transplantation; Nephrology; Department of Surgery, University of Florida, Gainesville, Florida; and Division of Nephrology, Gainesville Veterans Affairs Medical Center and University of Florida, Gainesville, Florida
Address correspondence to: Dr. Titte R. Srinivas, Kidney and Pancreas Transplant Program, University of Florida, Box 100224, 1600 SW Archer Road, Gainesville, FL 32610-0224. Phone: 352-846-2692; Fax: 352-392-5465; srinitr{at}medicine.ufl.edu
Cinacalcet, a calcimimetic, was evaluated in persistent hyperparathyroidism after kidney transplantation (Tx). Ten kidney transplant recipients and one kidney-pancreas recipient with persistent post-Tx hypercalcemia (serum calcium [SCa] > 10.2 mg/dl), stable graft function, and intact parathyroid hormone (iPTH) 
2 times normal received 30 mg/d cinacalcet between 2 mo and 5 yr after Tx. SCa, serum phosphorus (SP), and iPTH were measured before and after cinacalcet. Mean pre-cinacalcet SCa was 10.9 mg/dl (8.6 to 11.9 mg/dl). Average pre-cinacalcet SP was 2.9 mg/dl (1.8 to 4.0 mg/dl). Mean pre-cinacalcet iPTH was 267.0 pg/ml (99 to 723 pg/ml). After cinacalcet, SCa decreased on average by 1.6 mg/dl (95% confidence interval 1.2 to 2.1; P < 0.0001). Post-cinacalcet SP increased on average 0.45 mg/dl (P = 0.046). Post-cinacalcet iPTH averaged 156.9 mg/dl (P = 0.10). Graft function remained stable. Cinacalcet lowers SCa and raises SP in the short term in patients with persistent post-Tx hyperparathyroidism; long-term bone effects and persistent hyperparathyroidism merit further study.
Related Articles
Clin. J. Am. Soc. Nephrol. 2006 1: 170-171.
J. Am. Soc. Nephrol. 2006 17: 795-804.
This article has been cited by other articles:
|
|
 |
|
  P. Evenepoel, B. Van Den Bergh, M. Naesens, H. De Jonge, B. Bammens, K. Claes, D. Kuypers, and Y. Vanrenterghem Calcium Metabolism in the Early Posttransplantation Period Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kamar, I. Gennero, L. Spataru, L. Esposito, J. Guitard, L. Lavayssiere, O. Cointault, P. Gandia, D. Durand, and L. Rostaing Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3720 - 3726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goto, H. Komaba, and M. Fukagawa Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention NDT Plus, August 1, 2008; 1(suppl_3): iii2 - iii8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanaka, S. Nakanishi, H. Komaba, K. Itoh, K. Matsushita, and M. Fukagawa Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism NDT Plus, August 1, 2008; 1(suppl_3): iii49 - iii53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke, D. Martin, and M. Rodriguez Reply Nephrol. Dial. Transplant., January 1, 2008; 23(1): 408 - 409. [Full Text] [PDF]
|
|
|
|
|
|
M. Fukagawa and M. Taniguchi Can calcimimetics inhibit nodular hyperplasia of parathyroid glands? Nephrol. Dial. Transplant., January 1, 2008; 23(1): 407 - 408. [Full Text] [PDF]
|
|
|
|
|
|
M. Chonchol and R. P. Wuthrich Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease NDT Plus, January 1, 2008; 1(suppl_1): i36 - i41. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
